Teladoc Health (NYSE:TDOC) Given New $5.00 Price Target at BMO Capital Markets

Teladoc Health (NYSE:TDOC) had its target price reduced by BMO Capital Markets from $8.00 to $5.00 in a research note released on Thursday,Benzinga reports. They currently have a market perform rating on the health services provider’s stock.

Several other equities research analysts also recently commented on TDOC. Zacks Research downgraded Teladoc Health from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th. Stifel Nicolaus dropped their price objective on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Thursday. Piper Sandler reissued an “overweight” rating and set a $9.00 target price (down from $12.00) on shares of Teladoc Health in a research report on Thursday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Teladoc Health in a report on Monday, December 29th. Finally, Citigroup dropped their price target on shares of Teladoc Health from $10.00 to $9.00 and set a “neutral” rating on the stock in a research note on Friday, January 9th. Four investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Teladoc Health has an average rating of “Hold” and a consensus target price of $7.80.

Teladoc Health Price Performance

Teladoc Health stock opened at $5.35 on Thursday. The firm has a fifty day moving average of $6.03 and a 200-day moving average of $7.21. Teladoc Health has a 52-week low of $4.40 and a 52-week high of $10.02. The company has a quick ratio of 2.60, a current ratio of 2.70 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $949.46 million, a P/E ratio of -4.69 and a beta of 2.12.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings results on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. Teladoc Health had a negative net margin of 7.92% and a negative return on equity of 9.09%. The firm had revenue of $642.27 million during the quarter, compared to analysts’ expectations of $635.33 million. During the same period in the prior year, the company earned ($0.28) EPS. The firm’s revenue was up .3% on a year-over-year basis. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. As a group, analysts predict that Teladoc Health will post -1.16 EPS for the current year.

Insider Activity at Teladoc Health

In other Teladoc Health news, CEO Charles Divita III sold 17,138 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $7.63, for a total transaction of $130,762.94. Following the sale, the chief executive officer owned 201,036 shares in the company, valued at $1,533,904.68. This represents a 7.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Adam C. Vandervoort sold 5,720 shares of Teladoc Health stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $7.49, for a total value of $42,842.80. Following the completion of the transaction, the insider owned 80,732 shares of the company’s stock, valued at approximately $604,682.68. The trade was a 6.62% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 33,288 shares of company stock worth $251,684. 0.58% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Teladoc Health

A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in Teladoc Health by 4.2% during the third quarter. Vanguard Group Inc. now owns 21,910,950 shares of the health services provider’s stock valued at $169,372,000 after purchasing an additional 891,732 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Teladoc Health by 8.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 7,494,255 shares of the health services provider’s stock valued at $52,459,000 after buying an additional 605,061 shares during the period. Geode Capital Management LLC grew its position in shares of Teladoc Health by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 4,188,313 shares of the health services provider’s stock valued at $29,324,000 after buying an additional 18,394 shares during the last quarter. Jupiter Asset Management Ltd. raised its stake in Teladoc Health by 293.9% during the fourth quarter. Jupiter Asset Management Ltd. now owns 3,860,076 shares of the health services provider’s stock worth $27,021,000 after acquiring an additional 2,880,008 shares during the period. Finally, Nuveen LLC raised its stake in Teladoc Health by 38.7% during the fourth quarter. Nuveen LLC now owns 2,659,662 shares of the health services provider’s stock worth $18,618,000 after acquiring an additional 742,240 shares during the period. Institutional investors and hedge funds own 76.82% of the company’s stock.

Key Stories Impacting Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Q4 beat and narrower loss: Teladoc reported revenue of $642.3M (above estimates) and GAAP loss per share of $0.14 (better than consensus), driven by international growth and strength in Integrated Care; investors view the improved bottom line as a near-term positive. Teladoc Tops Q4 Earnings Estimates on International Growth & Lower Costs
• Positive Sentiment: Selective analyst support: Some firms are staying constructive (Bank of America upgraded to Buy, Piper Sandler reaffirmed Overweight, Canaccord remains a Buy despite lowering its PT), which bolsters demand from buyers who focus on recovery potential. Demystifying Teladoc Health: Insights From 8 Analyst Reviews
• Neutral Sentiment: Midterm growth roadmap: Management projects FY2026 revenue of roughly $2.47B–$2.59B and emphasized investments in AI, insurance relationships and international expansion — initiatives that support longer-term upside but will take time to materialize. Teladoc projects $2.47B–$2.59B revenue in 2026
• Negative Sentiment: Cautious forward guidance: Q1 2026 revenue guidance ($598M–$620M) and EPS guidance (-$0.45 to -$0.35) came in below Wall Street expectations, and FY EPS guidance (-$1.10 to -$0.70) is wider/weaker than consensus — a key reason for mixed investor reactions despite the quarter’s beat. Teladoc Health Reports Fourth Quarter and Full Year 2025 Results
• Negative Sentiment: Analyst price-target cuts: Several firms trimmed price targets (BMO, TD Cowen, Stifel, Wells Fargo, Leerink) and moved to Market Perform/Hold ratings in response to the softer outlook, adding selling pressure for investors focused on nearer-term valuation and earnings visibility. Analyst price-target updates

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.